KOA SHOJI HOLDINGS (9273) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period of the fiscal year ending March 2026, the Company posted increases in both revenue and profit, with profit growth exceeding revenue growth, indicating high-quality earnings. Revenue was ¥183.3B (¥176.2B in the same period of the previous year, +4.0% YoY), Operating Income was ¥45.8B (+4.5%), Ordinary Income was ¥45.5B (+3.0%), and Net Income attributable to owners of the parent was ¥30.5B (+3.1%). Growth in revenue and profit in the Active Pharmaceutical Ingredient Sales Business served as the primary driver. The Operating Income margin improved slightly from the same period of the previous year to 25.0%; however, a foreign exchange loss of ¥0.6B recorded as a non-operating expense restrained growth in Ordinary Income and Net Income.

Factors Affecting Earnings

【Revenue】Revenue increased 4.0% YoY to ¥183.3B. By segment, the Active Pharmaceutical Ingredient Sales Business generated ¥113.1B in revenue (from external customers, +5.3% YoY), driving growth as the core business, while the Pharmaceutical Manufacturing and Marketing Business recorded ¥70.2B (+2.1%), representing only moderate growth. Both businesses maintained revenue growth, but the primary growth driver was the Active Pharmaceutical Ingredient Sales Business.

【Profit and Loss】Operating Income increased 4.5% YoY to ¥45.8B, exceeding the rate of revenue growth. Segment profit in the Active Pharmaceutical Ingredient Sales Business rose substantially to ¥25.9B (+8.3%), while the Pharmaceutical Manufacturing and Marketing Business was essentially flat at ¥19.3B (-0.1%). The stagnation of the latter, which has a higher profit margin, restrained the extent of consolidated profit growth. Ordinary Income increased only 3.0% YoY to ¥45.5B, slowing relative to Operating Income growth. The main factor was a ¥0.6B foreign exchange loss recorded in non-operating expenses; the impact of ¥0.1B in interest expenses was minor. Extraordinary income and losses were negligible, consisting only of a ¥0.04B gain on the sale of fixed assets. The primary reason for the gap between Profit Before Tax and Net Income was the ¥15.0B burden of income taxes and other taxes, reflecting an effective tax rate of 33.0%. In conclusion, the Company recorded increases in both revenue and profit.

Segment Analysis

The Active Pharmaceutical Ingredient Sales Business recorded revenue of ¥122.5B (including intersegment transactions, +4.4% YoY), segment profit of ¥25.9B (+8.3%), and a profit margin of 21.1%, achieving profit growth exceeding revenue growth and leading overall profit growth. The Pharmaceutical Manufacturing and Marketing Business recorded revenue of ¥70.2B (+2.1%), segment profit of ¥19.3B (-0.1%), and a profit margin of 27.5%. Although its profit margin exceeded that of the Active Pharmaceutical Ingredient Sales Business, profit growth stagnated. Recovery in the profitability of the higher-margin Pharmaceutical Manufacturing and Marketing Business will be the focus for improving the consolidated margin going forward.

Key Financial Metrics

【Profitability】The Operating Income margin of 25.0% improved slightly from 24.9% in the same period of the previous year, and, together with a gross profit margin of 34.6%, the Company maintained a highly profitable structure. The Net Income margin was 16.6%, slightly down from 16.8% in the same period of the previous year, primarily due to the foreign exchange loss recorded in non-operating expenses. 【Cash Flow Quality】The effective tax rate was 33.0%, and the conversion rate from Profit Before Tax of ¥45.6B to Net Income of ¥30.5B was approximately 67%. 【Investment Efficiency】ROE was 10.0%, comprising a Net Income margin of 16.6%, total asset turnover of 0.48x, and financial leverage of 1.25x. High ROE under low financial leverage indicates a structure dependent more on core business profitability than on asset efficiency. 【Financial Soundness】The Equity Ratio increased to 80.2% from 77.9% in the previous year, while cash and deposits of ¥132.7B substantially exceeded current liabilities of ¥60.8B. The current ratio was approximately 421.6%, indicating a high level of short-term payment capacity.

Cash Flow Analysis

Although the Company did not disclose a cash flow statement, changes in the balance sheet provide insight into funding trends. Cash and deposits declined to ¥132.7B from ¥149.2B in the same period of the previous year, while property, plant and equipment increased to ¥104.7B from ¥92.0B. Of this amount, construction in progress of ¥47.2B accounted for 45.0% of property, plant and equipment. This composition indicates that funds are increasingly being invested in capital expenditures. Accounts receivable and notes receivable amounted to ¥38.1B; including electronically recorded monetary claims, the scale of capitalized operating receivables will remain an item requiring ongoing monitoring. Inventories increased to ¥27.7B from ¥21.2B in the previous year, indicating that inventory accumulation is tying up working capital. Short-term borrowings increased to ¥20.8B from ¥8.6B in the previous year, suggesting that a portion of capital expenditure funding may be financed through short-term borrowing.

Earnings Quality

Recurring earnings power is reflected in Operating Income of ¥45.8B and an Operating Income margin of 25.0%. Extraordinary income and losses were negligible, consisting of a ¥0.04B gain on the sale of fixed assets, indicating that the impact of one-time factors was extremely limited. Non-operating income and expenses resulted in a net loss, with income of ¥0.4B compared with expenses of ¥0.7B, primarily comprising a ¥0.6B foreign exchange loss. This foreign exchange loss was the main factor suppressing Ordinary Income growth to +3.0% compared with Operating Income growth of +4.5%; despite the underlying trend of core business profit growth, non-operating factors slightly weakened earnings quality. Comprehensive Income was ¥30.5B, broadly in line with Net Income. As fluctuations in valuation differences on securities and deferred hedge gains and losses were limited, the gap between Net Income and Comprehensive Income was minor.

Earnings Forecast and Guidance

The full-year earnings forecast is revenue of ¥257.0B (+10.4% YoY), Operating Income of ¥54.3B (+1.4%), and Ordinary Income of ¥54.3B (+1.0%), with no revision to the forecast for the current quarter. Cumulative Q3 progress rates were 71.3% for revenue, 84.3% for Operating Income, and 83.8% for Ordinary Income. Profit progress exceeded the standard 75%, while revenue progress was slightly below it. This difference reflects a conservative plan incorporating revenue of ¥73.7B and Operating Income of ¥8.5B (a profit margin of approximately 11.5%) in the remaining Q4, representing a substantial gap from the cumulative actual Operating Income margin of 25.0%. Revenue composition and expense recognition trends in Q4 are expected to determine the full-year outcome.

Shareholder Returns

The full-year dividend forecast is ¥18.00 per share. As the Q2 dividend was ¥0, the dividend policy is structured around concentrating the payment at fiscal year-end. Based on the full-year EPS forecast of ¥86.42, the Payout Ratio is approximately 20.8%, which is conservative when dividends alone are used as the numerator. The financial base of an Equity Ratio of 80.2% and cash and deposits of ¥132.7B supports the capacity to continue dividends, assuming profit progresses as planned. However, capital expenditures centered on construction in progress of ¥47.2B are underway, and balancing investment and shareholder returns will be an issue in future capital allocation.

Risk Factors

1. Regulatory and price competition risks in the pharmaceutical industry: The Active Pharmaceutical Ingredient Sales Business and Pharmaceutical Manufacturing and Marketing Business are susceptible to the impact of drug price revisions, price competition in the generic drug market, and compliance with GMP and the Pharmaceuticals and Medical Devices Act. Maintaining the high Operating Income margin of 25.0% requires preserving the product mix and quality assurance systems.

2. Risk of monetizing capital expenditures: Construction in progress of ¥47.2B accounts for 45.0% of property, plant and equipment of ¥104.7B. Delays in completion, cost overruns, or failure to achieve expected demand after commencement of operations could lead to lower asset efficiency and impairment risk.

3. Inventory and foreign exchange volatility risks: Inventories increased to ¥27.7B YoY, and inventory turnover trends will affect working capital efficiency. In addition, the ¥0.6B foreign exchange loss recorded in non-operating expenses may continue to cause fluctuations in Ordinary Income depending on the scale of foreign-currency-denominated transactions.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (trading)

Profitability and Returns

The Company's profitability substantially exceeds the industry median, with both its Operating Income margin and Net Income margin standing out within the industry.

Growth and Capital Efficiency

The Revenue growth rate was slightly below the industry median but remained within the IQR and was not exceptionally weak.

※Source: Compiled by the Company

Key Takeaways from the Earnings Results

1. The key feature of the current period was that growth in the Active Pharmaceutical Ingredient Sales Business—revenue +5.3% and profit +8.3%—led overall growth while the Company maintained a highly profitable structure, with an Operating Income margin of 25.0% and a Net Income margin of 16.6%.

2. Operating Income progress against the full-year forecast was 84.3%, exceeding the standard level; however, the planned Q4 profit margin of approximately 11.5% is substantially below the cumulative actual margin, creating a structure in which year-end expense recognition and changes in revenue composition will determine the full-year outcome.

3. Construction in progress of ¥47.2B, representing 45.0% of property, plant and equipment, and the increase in inventories are key items to monitor when assessing future capital efficiency and working capital efficiency.

Theoretical Share Price (Reference Value)

Sensitivity: ¥757–¥803 at a ±1% change in the Cost of Equity, and ¥778–¥782 at a ±0.1 change in ω.

Notes:

• Net assets as of the quarter-end are used (there is a timing gap relative to the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat high.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / This is a mechanically calculated value based solely on publicly disclosed data and is not a forecast of the market share price, a recommendation of any specific investment action, or a prediction or guarantee of future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2026 Q3 was a solid earnings release, with revenue and operating profit both increasing while already exceeding the normal three-quarter pace against full-year operating guidance. Revenue rose 4.0% year on year to ¥18.33bn. Operating income increased 4.5% to ¥4.58bn. Ordinary income grew 3.0% to ¥4.55bn. Net income attributable to owners rose 3.1% to ¥3.05bn, equivalent to EPS of ¥72.47. The operating margin improved by 10bp year on year to 25.0%, from 24.9%. Gross margin expanded by 190bp to 34.6%, demonstrating favorable gross-profit generation. This improvement was partly absorbed by SG&A, which increased 8.8% year on year to ¥1.76bn and rose as a share of revenue by 40bp to 9.6%. The resulting operating-profit growth remained slightly ahead of sales growth, indicating modest positive operating leverage at the EBIT level. Below operating income, ordinary-income growth lagged operating-income growth because foreign-exchange losses of ¥0.55bn and higher non-operating expenses reduced the benefit of operating improvement. The effective tax rate was 33.0%, producing a tax burden of 0.670x and limiting net-profit conversion relative to the 25.0% EBIT margin. Annualized ROE was 13.3%, a good level, supported mainly by a high 16.6% net margin rather than aggressive leverage. The balance sheet remains highly liquid, with cash and deposits of ¥13.27bn, a 421.6% current ratio, and a conservative 0.25x debt-to-equity ratio. However, short-term borrowings increased sharply and construction in progress reached ¥47.16bn, making execution and refinancing management important. Full-year guidance has not been revised, although Q3 cumulative operating income has reached 84.3% of the full-year target, 9.3 percentage points above the standard 75% seasonal benchmark. The principal forward-looking issue is whether investment in capacity under construction can be commissioned efficiently and sustain growth without diluting the company’s sector-leading profitability.

Profitability Analysis

The annualized DuPont ROE of 13.3% is composed of a 16.6% net profit margin, 0.643x asset turnover, and 1.25x financial leverage. The primary source of return is therefore profitability, not balance-sheet leverage: leverage is restrained and asset turnover is moderate for a manufacturing-led pharmaceutical supply chain. EBIT margin was 25.0%, while the interest burden was exceptionally strong at 0.995x, reflecting minimal financing-cost drag; interest coverage was 328.79x. The tax burden of 0.670x was the main reduction between operating profit and net income, consistent with the 33.0% effective tax rate. Revenue growth of 4.0% was accompanied by a 4.5% increase in operating income, and the operating margin expanded 10bp. Gross profit increased 5.7% to ¥6.34bn, faster than sales, with gross margin rising from 34.1% to 34.6%. SG&A increased 8.8% to ¥1.76bn, faster than revenue, and its ratio to sales rose from 9.2% to 9.6%; this is the principal factor tempering gross-margin-driven operating leverage. R&D spending increased 10.8% to ¥0.11bn but represented only 0.6% of sales. By segment, the core business by operating-profit contribution was the active pharmaceutical ingredient sales business, generating segment profit of ¥2.59bn, up 8.3% year on year, on external revenue of ¥11.31bn, up 5.3%. Its segment margin, measured against segment revenue including intersegment sales, improved from 20.4% to 21.1%. Pharmaceutical manufacturing and marketing generated external revenue of ¥7.02bn, up 2.1%, while segment profit was ¥1.93bn, down 0.1%; its segment margin declined from 28.1% to 27.5%. Accordingly, consolidated margin expansion was driven by the higher-profit contribution and margin improvement in API sales, while the manufacturing segment’s flat profit limits the breadth of the improvement. The 4.0% gain in revenue and absence of impairment or goodwill-related charges support a largely operating-led earnings outcome, although FX losses caused ordinary income to lag EBIT.

Growth Assessment

Growth was steady rather than high-paced, with consolidated revenue increasing 4.0% year on year to ¥18.33bn. API sales was the principal growth engine, adding ¥0.57bn of external revenue and ¥0.20bn of segment profit. Pharmaceutical manufacturing and marketing added ¥0.14bn of revenue, but its segment profit was essentially flat, indicating that revenue expansion in this business did not translate into incremental profitability during the period. Full-year company guidance calls for revenue of ¥25.70bn, up 10.4% year on year, operating income of ¥5.43bn, up 1.4%, ordinary income of ¥5.43bn, up 1.0%, and net income attributable to owners of ¥3.64bn. Q3 cumulative revenue represents 71.3% of the annual sales target, 3.7 percentage points below the standard 75% progress rate. In contrast, operating income is at 84.3% of guidance, 9.3 percentage points ahead of the standard pace, while net income is at 83.8% of guidance, 8.8 percentage points ahead. This profile implies that the implied Q4 revenue requirement is ¥7.37bn, while implied Q4 operating income is ¥0.85bn, or an 11.6% operating margin. The implied Q4 margin is materially below the Q3 cumulative 25.0% margin, consistent with management’s unchanged full-year forecast and suggesting conservatism, seasonality, planned costs, or a less favorable sales mix in the final quarter. Construction in progress of ¥47.16bn is substantial relative to the existing ¥104.71bn PPE base and may provide future production capacity, but converts growth potential into execution risk until assets are commissioned and utilized. The low 0.6% R&D intensity is a strategic consideration for a pharmaceutical-related group because sustained differentiation depends more heavily on product sourcing, manufacturing execution, regulatory capability, and customer relationships than internally funded innovation.

Financial Health

Financial health is strong on conventional liquidity and leverage measures. Current assets of ¥25.65bn exceeded current liabilities of ¥6.08bn by ¥19.57bn, producing a 421.6% current ratio and a 376.0% quick ratio. Cash and deposits of ¥13.27bn alone were 2.18x current liabilities and 6.38x short-term debt. Total interest-bearing debt was ¥3.13bn, equivalent to 0.25x equity and 9.3% of total capital. Total liabilities represented only 19.8% of total assets, while equity was ¥30.49bn, or 80.2% of assets. There is no current-ratio or debt-to-equity warning: both are substantially stronger than the relevant risk thresholds. Interest expense of ¥0.14bn is readily serviceable against ¥4.58bn of operating income. The refinancing-risk alert nevertheless warrants attention because short-term loans increased 141.9% year on year to ¥2.08bn and comprise 66.6% of interest-bearing debt, above the 40% alert threshold. This maturity concentration is mitigated materially by cash holdings, but it indicates a greater reliance on short-dated funding than in the prior year. Investment securities rose from ¥0.90bn to ¥16.64bn, an increase of ¥15.74bn or 1,750.5%, raising market-value and capital-allocation sensitivity despite the group’s ample equity buffer. Inventories increased 30.6% to ¥27.74bn and inventory days reached 63 days, above the 60-day alert threshold; this should be monitored against production plans and demand conversion. Accounts receivable declined to ¥3.81bn, while electronically recorded monetary claims declined to ¥4.12bn, partly offsetting the inventory build in operating working capital. No material goodwill burden is evident, and intangible assets are only ¥0.08bn, so balance-sheet value is primarily tangible and liquid rather than acquisition-accounting dependent.

Notable B/S Changes

Investment securities: +¥15.74bn (+1,750.5%) to ¥16.64bn - substantially increases exposure to securities valuation movements and raises the importance of investment-return discipline. Short-term loans: +¥12.20bn (+141.9%) to ¥20.80bn - increased reliance on short-dated funding; cash of ¥132.67bn provides strong coverage, but maturity management remains relevant. Inventories: +¥6.50bn (+30.6%) to ¥27.74bn - inventory days reached 63, requiring monitoring of demand conversion, obsolescence risk, and working-capital efficiency. Construction in progress: +¥14.76bn (+45.6%) to ¥47.16bn - major capacity investment; the scale of uncommissioned assets heightens execution, cost-overrun, and utilization risk.

Cash Flow Quality

The earnings profile is supported by strong operating profitability, with cumulative net income of ¥3.05bn and a 16.6% net margin. Working-capital trends are mixed: trade receivables declined by ¥0.24bn and electronically recorded monetary claims declined by ¥0.43bn year on year, both supportive of cash conversion. Conversely, inventories rose by ¥0.65bn, or 30.6%, and the 63-day inventory level is above the stated alert threshold. The inventory increase may reflect production preparation, safety-stock accumulation, or expected demand, but it raises the importance of sell-through and inventory-obsolescence control in a pharmaceutical supply chain. Construction in progress increased by ¥14.76bn year on year to ¥47.16bn and accounts for 45.0% of PPE, well above the 20% high-CIP alert threshold. This is a material deployment of capital into assets not yet contributing fully to productive capacity, so commissioning discipline, budget control, and eventual utilization are central to future cash conversion. The absence of goodwill or reported impairment charges means reported profit is not affected by amortization or impairment from acquisition accounting. The ¥0.04bn gain on sale of fixed assets was immaterial relative to ¥3.05bn net income, so it does not materially affect recurring earnings assessment. Foreign-exchange losses of ¥0.55bn were more meaningful, reducing ordinary income but representing a below-operating-profit item rather than a deterioration in core operating margin.

Dividend Sustainability

The full-year dividend forecast is ¥18.00 per share. Against forecast EPS of ¥86.42, the prospective dividend payout ratio is 20.8%, well below the 60% sustainability benchmark. The prospective cash dividend requirement is approximately ¥0.76bn based on 42.12 million shares outstanding. This is modest relative to Q3 cumulative net income of ¥3.05bn, retained earnings of ¥281.12bn, and cash and deposits of ¥13.27bn. The large retained-earnings base and low 0.25x debt-to-equity ratio provide substantial balance-sheet capacity to maintain the indicated dividend. However, the company is simultaneously carrying ¥47.16bn of construction in progress, making the pace and returns of capacity investment more relevant to future capital-allocation flexibility than the current payout ratio. The zero Q2 DPS is consistent with an apparent year-end-focused distribution structure rather than evidence of reduced full-year shareholder returns. No dividend forecast revision has been announced.

Risk Assessment

Business risks include API sales is the core profit contributor; customer concentration, pricing pressure, supplier disruption, pharmaceutical regulatory compliance, and quality-control events could affect the largest earnings stream., Pharmaceutical manufacturing and marketing revenue increased 2.1% but segment profit declined 0.1%, indicating margin pressure or unfavorable mix that could persist if cost recovery remains limited., Inventory days of 63 exceed the 60-day alert threshold. The ¥6.50bn year-on-year inventory increase creates risks of slower demand conversion, product obsolescence, and working-capital absorption., R&D intensity of 0.6% is below the 3% alert threshold. For a pharmaceutical-related group, lower internal R&D investment can heighten reliance on external product pipelines, sourcing, manufacturing know-how, and commercial execution., Foreign-exchange losses of ¥0.55bn demonstrate exposure to currency movements, which can affect imported raw-material costs, procurement economics, and non-operating earnings..

Financial risks include Short-term loans increased 141.9% to ¥2.08bn and short-term debt represents 66.6% of total interest-bearing debt. This refinancing-risk alert reflects increased maturity concentration, although ¥13.27bn of cash and a 6.38x cash-to-short-term-debt ratio provide substantial coverage., Construction in progress increased ¥14.76bn year on year to ¥47.16bn and represents 45.0% of PPE, above the 20% alert threshold. Delays, cost overruns, regulatory approval issues, or low post-completion utilization could weaken returns on invested capital., Investment securities increased ¥15.74bn to ¥16.64bn. The larger securities balance introduces greater exposure to valuation movements and requires disciplined assessment of strategic and financial returns., The effective tax rate of 33.0% and tax burden of 0.670x reduce conversion of pre-tax profit to net income relative to the high EBIT margin..

Key concerns include Highest priority: execution of the very large construction-in-progress program, given its scale relative to the current PPE base and the need to convert capital spending into productive, regulated capacity., High priority: monitoring inventory turnover and manufacturing-segment margins, as inventory days are elevated and the manufacturing segment did not deliver profit growth., Moderate priority: short-term debt refinancing discipline. Liquidity is strong, but the funding mix has become materially more short-term., Moderate priority: sustaining API sales margin expansion while SG&A continues to grow faster than revenue., Moderate priority: foreign-exchange volatility, which already caused ordinary-income growth to trail operating-income growth..

Investment Implications

Key takeaways include Core earnings remained robust: operating income grew 4.5% to ¥4.58bn and the operating margin improved 10bp to 25.0%., API sales was the principal contributor to growth, with segment profit rising 8.3%, while pharmaceutical manufacturing and marketing profit was flat., Q3 cumulative operating income reached 84.3% of full-year guidance, compared with a standard 75% pace, while revenue progress was 71.3%., Liquidity and solvency are strong, supported by ¥13.27bn cash, a 421.6% current ratio, and 0.25x debt-to-equity., The major balance-sheet issue is capital deployment: construction in progress of ¥47.16bn is large and requires successful commissioning and utilization..

Metrics to watch include API sales revenue growth, segment margin, and segment-profit contribution, Pharmaceutical manufacturing and marketing segment margin and profit recovery, Construction-in-progress commissioning timing, cost control, and post-completion asset utilization, Inventory days, finished-goods balances, and inventory write-down risk, Short-term debt balance, maturity profile, and cash-to-short-term-debt coverage, Investment-securities balance and valuation movements, Foreign-exchange gains or losses and their effect on ordinary-income conversion, SG&A growth relative to revenue growth and operating-margin retention.

Regarding relative positioning, The company exhibits profitability and capital strength above typical benchmark levels, with a 25.0% operating margin, 16.6% net margin, 13.3% annualized ROE, very high liquidity, and low leverage. Its relative profile is therefore defined less by balance-sheet stress than by execution risk around a sizable tangible-capacity buildout, inventory management, and the ability to preserve API-led margins as the manufacturing business and investment program evolve.